跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
CO-1
首页
药物
CO-1
CO-1
未知生产厂商
订阅
生成 AI 研报
Share to Twitter
Share to Facebook
Share to LinkedIn
Share to Reddit
摘要
临床试验
审批记录
专利
每项发明一条,涵盖美国、欧洲、PCT 与中国的同族专利。
CO-AGONISTS OF THE GLP-1 AND AMYLIN RECEPTORS
EP 4263581 A1
申请人: NOVO NORDISK AS
优先权: 2020
CN
EP
US
WO
11 件公开
SALTS OR CO-CRYSTALS OF 3-(3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL)-PHENOL
EP 3287447 A1
申请人: GRUENENTHAL GMBH
优先权: 2010
CN
EP
US
9 件公开
Glucagon/GLP-1 receptor co-agonists
US 8454971 B2
申请人: DAY JONATHAN
优先权: 2008
EP
US
7 件公开
US 9156902 B2
申请人: DIMARCHI RICHARD D
优先权: 2012
US
6 件公开
US 8546327 B2
申请人: DIMARCHI RICHARD D
优先权: 2008
CN
US
5 件公开
US 8729017 B2
申请人: DIMARCHI RICHARD D
优先权: 2012
CN
US
5 件公开
US 8703701 B2
申请人: DIMARCHI RICHARD D
优先权: 2010
US
2 件公开
CONTINUOUS ADMINISTRATION OF EXENATIDE AND CO-ADMINSTRATION OF ACETAMINOPHEN, ETHINYLESTRADIOL OR LEVONORGESTREL
EP 3565580 B1
申请人: I2O THERAPEUTICS INC
优先权: 2017
CN
EP
US
5 件公开
GABAA POSITIVE ALLOSTERIC MODULATOR COMPOUNDS, METHODS OF MAKING, AND USES THEREOF
EP 3781566 A4
申请人: NEUROCYCLE THERAPEUTICS INC
优先权: 2018
CN
EP
US
5 件公开
CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
EP 3825324 A1
申请人: MERCK SHARP & DOHME
优先权: 2014
CN
EP
US
3 件公开
US 10493125 B2
申请人: MERCK SHARP & DOHME
优先权: 2016
US
STAPLED OLEFIN CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
EP 3842449 A1
申请人: MERCK SHARP & DOHME
优先权: 2019
CN
EP
US
3 件公开
CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY
EP 4185607 A1
申请人: NOVO NORDISK AS
优先权: 2020
CN
EP
US
3 件公开
PHARMACEUTICAL COMPOSITION CONTAINING 1-{2-[(3S,4R)-1-{[(3R,4R)-1-CYCLOPENTYL-3-FLUORO-4-(4-METHOXYPHENYL)PYRROLIDINE-3-YL]CARBONYL}-4-(METHOXYMETHYL)PYRROLIDINE-3-YL]-5-(TRIFLUOROMETHYL)PHENYL}PIPERIDINE-4-CARBOXYLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT OR CO-CRYSTAL THEREOF
EP 4566609 A1
申请人: MITSUBISHI TANABE PHARMA CORP
优先权: 2022
CN
EP
US
3 件公开
COMBINATION OF NY-ESO-1 SPECIFIC T CELL RECEPTORS AND CHIMERIC CO-STIMULATORY RECEPTORS
US 20260055159 A1
申请人: MEDIGENE IMMUNOTHERAPIES GMBH
优先权: 2022
CN
US
WO
3 件公开
第 1 / 10 页
上一页
下一页
药物
反馈